<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">BMC Res Notes</journal-id>
      <journal-id journal-id-type="iso-abbrev">BMC Res Notes</journal-id>
      <journal-title-group>
        <journal-title>BMC Research Notes</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1756-0500</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25214394</article-id>
      <article-id pub-id-type="pmc">4167504</article-id>
      <article-id pub-id-type="publisher-id">3156</article-id>
      <article-id pub-id-type="doi">10.1186/1756-0500-7-635</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Use of lithium in clozapine-induced neutropenia: a case report</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Suraweera</surname>
            <given-names>Chathurie</given-names>
          </name>
          <address>
            <email>dr.chathurie@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff50"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hanwella</surname>
            <given-names>Raveen</given-names>
          </name>
          <address>
            <email>raveenhanwella@yahoo.co.uk</email>
          </address>
          <xref ref-type="aff" rid="Aff51"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>de Silva</surname>
            <given-names>Varuni</given-names>
          </name>
          <address>
            <email>varunidesilva2@yahoo.co.uk</email>
          </address>
          <xref ref-type="aff" rid="Aff51"/>
        </contrib>
        <aff id="Aff50"><label/>University Psychological Medicine Unit, National Hospital of Sri Lanka, Colombo, Sri Lanka </aff>
        <aff id="Aff51"><label/>Department of Psychological Medicine, Faculty of Medicine, Kynsey Road, Colombo 08, Sri Lanka </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>12</day>
        <month>9</month>
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>12</day>
        <month>9</month>
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2014</year>
      </pub-date>
      <volume>7</volume>
      <elocation-id>635</elocation-id>
      <history>
        <date date-type="received">
          <day>8</day>
          <month>7</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>9</day>
          <month>9</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Suraweera et al.; licensee BioMed Central Ltd. 2014</copyright-statement>
        <license license-type="open-access">
          <license-p>This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Background</title>
          <p>The literature describing the long-term use of lithium carbonate to reinstate reduced levels of white blood cell counts in patients treated with clozapine is scarce. We describe a case of successful recommencement of clozapine on a patient who developed risk level of neutropenia which was corrected by lithium carbonate. He was followed up for a period of one year.</p>
        </sec>
        <sec>
          <title>Case presentation</title>
          <p>We report a 40-year-old Sri Lankan male who developed neutropenia and low white blood cell counts following commencement of clozapine. We were successful in restarting clozapine after the addition of lithium carbonate to increase the cell counts. Clozapine was increased to 700 mg a day with 500 mg of lithium carbonate. The patient remains stable after one year with no further episodes of neutropenia.</p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p>Lithium carbonate can successfully be used to treat clozapine-induced neutropenia.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Neutropenia</kwd>
        <kwd>Clozapine</kwd>
        <kwd>Lithium carbonate</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2014</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Background</title>
      <p>It is estimated that approximately 30% of patients with schizophrenia are resistant to typical and atypical antipsychotics and warrant treatment with clozapine. Clozapine should be offered to patients with treatment resistant schizophrenia (TRS) as it is the antipsychotic with most robust evidence for improving psychopathology and the quality of life [<xref ref-type="bibr" rid="CR1">1</xref>]. However, clozapine carries a 0.9% risk of causing agranulocytosis and 2.7% risk of neutropenia [<xref ref-type="bibr" rid="CR2">2</xref>] which could be fatal. Over 80% of such cases are seen within the first 18 weeks of treatment. Some patients who develop agranulocytosis may be genetically predisposed [<xref ref-type="bibr" rid="CR3">3</xref>].</p>
      <p>As a result, most clinicians are reluctant to initiate clozapine on patients. Lithium carbonate has been known to increase the white blood cell (WBC) counts in patients with leucocytopenia due to oncological causes. This has prompted clinicians to explore the possibility of using lithium carbonate in clozapine-induced neutropenia.</p>
    </sec>
    <sec id="Sec2">
      <title>Case presentation</title>
      <p>Our patient is a 40-year-old Sri Lankan male who was diagnosed with paranoid schizophrenia at the age of 22 years and was resistant to adequate trials of trifluoperazine, olanzapine and risperidone. Therefore, he was started on clozapine. The patient had delusions of reference, delusional perception and commanding hallucinations which affected his day to day functioning to a great degree. He lost his job as a result of ongoing psychopathology.</p>
      <p>His baseline white cell counts were only marginally higher than the levels recommended before initiating treatment with clozapine. The effect of clozapine and lithium carbonate on the leucocyte count of the patient is given in Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1"><label>Table 1</label><caption><p>
<bold>Effect of clozapine and lithium carbonate on white blood cell and neutrophil counts</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Day</th><th>0</th><th>1</th><th>7</th><th>9</th><th>10</th><th>11</th><th>13</th><th>14</th><th>16</th><th>20</th><th>27</th><th>34</th></tr></thead><tbody><tr><td>
<bold>Total dose of clozapine (mg)</bold>
</td><td align="right"/><td align="center">12.5</td><td align="center">50</td><td align="center">62.5</td><td align="center">0</td><td align="right"/><td align="right"/><td align="center">12.5</td><td align="right"/><td align="center">50</td><td align="center">75</td><td align="center">150</td></tr><tr><td>
<bold>Dose of lithium carbonate (mg)</bold>
</td><td align="right"/><td align="right"/><td align="right"/><td align="right"/><td align="center">250</td><td align="center">500</td><td align="center">500</td><td align="center">500</td><td align="center">500</td><td align="center">500</td><td align="center">500</td><td align="center">500</td></tr><tr><td>
<bold>White cell count (10</bold>
<sup><bold>3</bold></sup>
<bold>/&#x3BC;l)</bold>
</td><td align="center">6.03</td><td align="right"/><td align="center">5.8</td><td align="center">4.9</td><td align="right"/><td align="right"/><td align="right"/><td align="center">6.3</td><td align="center">6.2</td><td align="center">7.4</td><td align="center">7.8</td><td align="center">8.3</td></tr><tr><td>
<bold>Neutrophil count (10</bold>
<sup><bold>3</bold></sup>
<bold>/&#x3BC;l)</bold>
</td><td align="center">2.82</td><td align="right"/><td align="center">2.4</td><td align="center">2.0</td><td align="right"/><td align="right"/><td align="right"/><td align="center">2.6</td><td align="center">3.4</td><td align="center">3.7</td><td align="center">3.7</td><td align="center">3.0</td></tr></tbody></table></table-wrap></p>
      <p>In order to initiate clozapine, patients must have a baseline WBC count of 4.0 &#xD7;10<sup>3</sup>/&#x3BC;l and a neutrophil count of 2.5 &#xD7; 10<sup>3</sup>/&#x3BC;l. Clozapine must be withheld if the WBC count drops below the &#x2018;red&#x2019; cut-off of 3.0 &#xD7; 10<sup>3</sup>/&#x3BC;l or the neutrophil count falls below 1.5 &#xD7; 10<sup>3</sup>/&#x3BC;l.</p>
      <p>In patients with benign ethnic neutropenia, the neutrophil count before commencement of clozapine is low and persistently tends to be around the risk level. Our patient had a low baseline WBC count of 6.02 &#xD7; 10<sup>3</sup>/&#x3BC;l and a neutrophil count of 2.82 &#xD7; 10<sup>3</sup>/&#x3BC;l before initiation of clozapine. The WBC and neutrophil counts decreased to 4.9 &#xD7; 10<sup>3</sup>/&#x3BC;l and 2.0 &#xD7; 10<sup>3</sup>/&#x3BC;l respectively, at a clozapine dose of 62.5 mg on day 9. In such patients lack of exercise, being a non-smoker or simply having blood drawn at the wrong time of day could result in clozapine treatment having to be stopped resulting in negative consequences for the patient [<xref ref-type="bibr" rid="CR4">4</xref>]. Approximately 90% of WBC remains in storage in the bone marrow. The total lifespan of a neutrophil is 11-14 days but they die within hours after entering the circulation. Infection stimulates release and can triple the WBC count in a matter of hours. Neutrophils can either circulate freely in the bloodstream or marginate after being released from the bone marrow.</p>
      <p>Lithium increases the neutrophil count and total WBC count both acutely and chronically [<xref ref-type="bibr" rid="CR5">5</xref>]. This &#x2018;side-effect&#x2019; of lithium has been used successfully to raise the WBC during cancer chemotherapy and in patients treated with carbamazepine. The mechanism by which lithium increases neutrophil count is not completely understood and the effect is poorly quantified. Neutrophilia does not seem to be clearly dose related although a minimum lithium serum level of 0.4 mmol/l may be required. A mean neutrophil count of 11.9 &#xD7; 10<sup>3</sup>/&#x3BC;l with a mean rise of 2.6 &#xD7; 10<sup>3</sup>/&#x3BC;ls has been reported in patients treated with lithium [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>].</p>
      <p>We restarted clozapine at a lithium level of 0.5 mmol/l on day 14 in our patient when he had a neutrophil count of 2.6 &#xD7; 10<sup>3</sup>/&#x3BC;l and a WBC count of 6.3 &#xD7; 10<sup>3</sup>/&#x3BC;l. He had a mean neutrophil count of 5.16 &#xD7; 10<sup>3</sup>/&#x3BC;l and a mean WBC count of 10.14 &#xD7; 10<sup>3</sup>/&#x3BC;l 6 months after initiation of lithium. At 1 year he had a WBC count of 8.6 &#xD7; 10<sup>3</sup>/&#x3BC;l and a neutrophil count of 5.2 &#xD7; 10<sup>3</sup>/&#x3BC;l. His mean lithium level at the end of 6 months was 0.55mmol/l. and 0.43 mmol/l at the end of one year (Figure&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1"><label>Figure 1</label><caption><p>
<bold>Effect of clozapine and lithium carbonate on white blood cell and neutrophil counts.</bold> The white blood cell and neutrophil counts dropped to 4.9 &#xD7; 10<sup>3</sup>/&#x3BC;l and 2.0 &#xD7; 10<sup>3</sup>/&#x3BC;l respectively at a clozapine dose of 62.5mg/d. It increased to 6.3 &#xD7; 10<sup>3</sup>/&#x3BC;l and 2.6 &#xD7;10<sup>3</sup>/&#x3BC;l after addition of lithium carbonate.</p></caption><graphic xlink:href="13104_2014_3156_Fig1_HTML" id="d30e557"/></fig></p>
    </sec>
    <sec id="Sec3" sec-type="conclusions">
      <title>Conclusion</title>
      <p>Our patient remains well and is currently employed. However, there are potential risks that should be borne in mind. Re-challenge with clozapine have faced with successes [<xref ref-type="bibr" rid="CR8">8</xref>] and failures. In a retrospective review of 53 cases of clozapine re-challenge in the United Kingdom and Ireland, 62% of the patients did not develop a blood dyscrasia [<xref ref-type="bibr" rid="CR9">9</xref>]. In 85% of the cases that developed a blood dyscrasia on re-challenge, it occurred sooner, lasted longer and was more severe than with the initial trial of clozapine. Therefore, when deciding on re-challenge with clozapine, clinicians must carefully weigh the risks and benefits. Not only the possibility of another episode of neutropenia, but toxic effects of lithium and other side effects of clozapine need particular attention.</p>
    </sec>
    <sec id="Sec4">
      <title>Consent</title>
      <p>Written informed consent was obtained from the patient for publication of this case report. A copy of the written consent is available for review by the Editor-in-Chief of this journal.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn>
        <p>
          <bold>Competing interests</bold>
        </p>
        <p>The authors declare that they have no competing interests.</p>
      </fn>
      <fn>
        <p>
          <bold>Authors&#x2019; contributions</bold>
        </p>
        <p>RH and VS supervised CS in the management of the patient. CS, RH and VS wrote the manuscript. All authors read and approved the final manuscript.</p>
      </fn>
    </fn-group>
    <ack>
      <title>Acknowledgment</title>
      <p>We would like to acknowledge Dr. U T Perera for his contribution with design and editing.</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kane</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <article-title>Clinical efficacy of clozapine in treatment-refractory schizophrenia: an overview</article-title>
          <source>Br J Psychiatry Suppl</source>
          <year>1992</year>
          <volume>17</volume>
          <fpage>41</fpage>
          <lpage>45</lpage>
          <pub-id pub-id-type="pmid">1418888</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lieberman</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
          <article-title>Maximizing clozapine therapy: managing side effects</article-title>
          <source>J Clin Psychiatry</source>
          <year>1998</year>
          <volume>59</volume>
          <issue>3</issue>
          <fpage>38</fpage>
          <lpage>43</lpage>
          <pub-id pub-id-type="pmid">9541337</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Munro</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>O&#x2019;sullivan</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Andrews</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Arana</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mortimer</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kerwin</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance</article-title>
          <source>Br J Psychiatry</source>
          <year>1999</year>
          <volume>175</volume>
          <fpage>576</fpage>
          <lpage>580</lpage>
          <pub-id pub-id-type="doi">10.1192/bjp.175.6.576</pub-id>
          <pub-id pub-id-type="pmid">10789357</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Abramson</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Melton</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Leukocytosis: basics of clinical assessment</article-title>
          <source>Am Fam Physician</source>
          <year>2000</year>
          <volume>62</volume>
          <fpage>2053</fpage>
          <lpage>2057</lpage>
          <pub-id pub-id-type="pmid">11087187</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lapierre</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Stewart</surname>
              <given-names>RB</given-names>
            </name>
          </person-group>
          <article-title>Lithium carbonate and leukocytosis</article-title>
          <source>Am J Hosp Pharm</source>
          <year>1980</year>
          <volume>37</volume>
          <fpage>1525</fpage>
          <lpage>1528</lpage>
          <pub-id pub-id-type="pmid">7211857</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Blier</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Slater</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Measham</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Koch</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wiviott</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Lithium and clozapine-induced neutropenia/agranulocytosis</article-title>
          <source>Int Clin Psychopharmacol</source>
          <year>1998</year>
          <volume>13</volume>
          <fpage>137</fpage>
          <lpage>140</lpage>
          <pub-id pub-id-type="doi">10.1097/00004850-199805000-00008</pub-id>
          <pub-id pub-id-type="pmid">9690982</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Paton</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Esop</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Managing clozapine-induced neutropenia with lithium</article-title>
          <source>Psychiatr Bull</source>
          <year>2005</year>
          <volume>29</volume>
          <fpage>186</fpage>
          <lpage>188</lpage>
          <pub-id pub-id-type="doi">10.1192/pb.29.5.186</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ghaznavi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Nakic</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Rao</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Jian</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Brewer</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Hannestad</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Bhagwagar</surname>
              <given-names>Z</given-names>
            </name>
          </person-group>
          <article-title>Rechallenging with clozapine following neutropenia: treatment options for refractory schizophrenia</article-title>
          <source>Am J Psychiatry</source>
          <year>2008</year>
          <volume>165</volume>
          <fpage>813</fpage>
          <lpage>818</lpage>
          <pub-id pub-id-type="doi">10.1176/appi.ajp.2008.07111823</pub-id>
          <pub-id pub-id-type="pmid">18593787</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Atkin</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kendall</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Gould</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Freeman</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Liberman</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>O Sullivan</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland</article-title>
          <source>Br J Psychiatr</source>
          <year>1996</year>
          <volume>169</volume>
          <fpage>483</fpage>
          <lpage>488</lpage>
          <pub-id pub-id-type="doi">10.1192/bjp.169.4.483</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
